0001626199-23-000022.txt : 20230105
0001626199-23-000022.hdr.sgml : 20230105
20230105190156
ACCESSION NUMBER: 0001626199-23-000022
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230104
FILED AS OF DATE: 20230105
DATE AS OF CHANGE: 20230105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rickey James Paul
CENTRAL INDEX KEY: 0001606243
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37449
FILM NUMBER: 23513043
MAIL ADDRESS:
STREET 1: ALPINE IMMUNE SCIENCES, INC.
STREET 2: 188 EAST BLAINE STREET, SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC.
CENTRAL INDEX KEY: 0001626199
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208969493
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-788-4545
MAIL ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Nivalis Therapeutics, Inc.
DATE OF NAME CHANGE: 20150211
FORMER COMPANY:
FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141121
4
1
wf-form4_167296329686813.xml
FORM 4
X0306
4
2023-01-04
0
0001626199
ALPINE IMMUNE SCIENCES, INC.
ALPN
0001606243
Rickey James Paul
C/O ALPINE IMMUNE SCIENCES, INC.
188 EAST BLAINE STREET, SUITE 200
SEATTLE
WA
98102
0
1
0
0
See Remarks
Stock Option (Right to buy)
7.55
2023-01-04
4
A
0
109000
0
A
2033-01-03
Common Stock
109000.0
109000
D
The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.
Senior Vice President, Chief Financial Officer and Corporate Secretary
/s/ James Paul Rickey
2023-01-05